Cargando…
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study
INTRODUCTION: Binge eating disorder (BED) is associated with obesity and major depressive disorder (MDD). Naltrexone extended-release (ER)/bupropion ER (NB) is approved as an adjunct to diet and physical activity for chronic weight management. In a prospectively designed 24-week open-label, single-a...
Autores principales: | Guerdjikova, Anna I., Walsh, Brandon, Shan, Kevin, Halseth, Amy E., Dunayevich, Eduardo, McElroy, Susan L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656719/ https://www.ncbi.nlm.nih.gov/pubmed/28918581 http://dx.doi.org/10.1007/s12325-017-0613-9 |
Ejemplares similares
-
Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study
por: McElroy, Susan L., et al.
Publicado: (2013) -
Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018) -
Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
por: Pi-Sunyer, Xavier, et al.
Publicado: (2019) -
Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
por: Halseth, Amy, et al.
Publicado: (2016) -
Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)